Who Generates Higher Gross Profit? Biogen Inc. or Grifols, S.A.

Biogen's Gross Profit Dominance Over Grifols: A Decade in Review

__timestamp	Biogen Inc.	Grifols, S.A.
Wednesday, January 1, 2014	8532288000	1699214000
Thursday, January 1, 2015	9523400000	1930998000
Friday, January 1, 2016	9970100000	1912291000
Sunday, January 1, 2017	10643900000	2152011000
Monday, January 1, 2018	11636600000	2049560000
Tuesday, January 1, 2019	12422500000	2341232000
Wednesday, January 1, 2020	11639400000	2255165000
Friday, January 1, 2021	8872000000	1962596000
Saturday, January 1, 2022	7895100000	2231530000
Sunday, January 1, 2023	7302200000	2322701000
Monday, January 1, 2024	9675900000

Cracking the code

Biogen Inc. vs. Grifols, S.A.: A Decade of Gross Profit Analysis

In the competitive landscape of the pharmaceutical industry, understanding who leads in profitability can offer valuable insights. Over the past decade, Biogen Inc. has consistently outperformed Grifols, S.A. in terms of gross profit. From 2014 to 2023, Biogen's gross profit peaked in 2019, reaching approximately 12.4 billion, while Grifols' highest was around 2.3 billion in the same year. Despite a decline in Biogen's profits by 41% from 2019 to 2023, it still maintained a higher average gross profit, nearly five times that of Grifols. This trend highlights Biogen's robust market position, although recent years show a narrowing gap. As the industry evolves, these financial dynamics could shift, making it crucial for investors and analysts to keep a close watch on future developments.

Published by

U.S. Securities and Exchange Commission

Source link

sec.gov

Date published

17 Jan 2025